MVA85A (modified vaccinia Ankara 85A) is a new-generation vaccine against tuberculosis developed by researchers at Oxford University. This vaccine produces higher levels of long-lasting cellular immunity when used together with the older TB vaccine BCG. Phase I clinical trials have been completed and phase II clinical trials are currently underway in South Africa. As of late 2010, those trials, while promising, were not expected to be finished until late 2015, with efficacy trials running in parallel from 2009 to 2019. By contrast, results released in February 2013 were described as "disappointing", showing only a statistically insignificant prevention rate in infants. Results published in 2015 bring the further doubt on the efficacy of the vaccine.
- McShane H, Pathan AA, Sander CR, et al. (2004). "Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG primed and naturally acquired anti-microbial immunity in humans". Nat Med 10 (11): 1240–44. doi:10.1038/nm1128. PMID 15502839.
- Hawkridge T, Scriba TJ, Gelderbloem S, et al. (2008). "Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa". J Infect Dis 198 (4): 544–52. doi:10.1086/590185. PMC 2822902. PMID 18582195.
- Ibanga H, Brookes R, Hill P, Owiafe P, Fletcher H, Lienhardt C, Hill A, Adegbola R, McShane H (2006). "Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design". Lancet Infect Dis 6 (8): 522–8. doi:10.1016/S1473-3099(06)70552-7. PMID 16870530.
- McShane H (23 September 2010). "Improving BCG with MVA85A: An update on clinical trials" (PDF). The Jenner Institute. Retrieved 2 October 2012.
- Walsh, Fergus (4 February 2013). "Tuberculosis vaccine hopes dashed". BBC News. Retrieved 4 February 2013.
- "Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review". Ije.oxfordjournals.org. Retrieved 2015-09-09.
|This vaccine article is a stub. You can help Wikipedia by expanding it.|